284 related articles for article (PubMed ID: 29064732)
1. Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III: Perspective for AAV-Mediated Gene Therapy.
Fu H; Meadows AS; Pineda RJ; Kunkler KL; Truxal KV; McBride KL; Flanigan KM; McCarty DM
Hum Gene Ther Clin Dev; 2017 Dec; 28(4):187-196. PubMed ID: 29064732
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Pre-Existing Neutralizing Antibodies Against Adeno-Associated Virus Serotypes 1, 2, 5, 6, 8, and 9 in Sera of Different Pig Strains.
Dai Y; Kavita U; Lampen MH; Gielen S; Banks G; Levesque P; Kozhich A; Pillutla R; Zhang Y; Jawa V; Adam L
Hum Gene Ther; 2022 Apr; 33(7-8):451-459. PubMed ID: 34913759
[TBL] [Abstract][Full Text] [Related]
3. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
[TBL] [Abstract][Full Text] [Related]
4. IgG-cleavage protein allows therapeutic AAV gene delivery in passively immunized MPS IIIA mice.
Bobo TA; Samowitz PN; Robinson MI; Montes LI; Forsberg LJ; Feng R; Nicely NI; Fu H
Gene Ther; 2023 Apr; 30(3-4):377-385. PubMed ID: 36253453
[TBL] [Abstract][Full Text] [Related]
5. Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort.
Perocheau DP; Cunningham S; Lee J; Antinao Diaz J; Waddington SN; Gilmour K; Eaglestone S; Lisowski L; Thrasher AJ; Alexander IE; Gissen P; Baruteau J
Hum Gene Ther; 2019 Jan; 30(1):79-87. PubMed ID: 30027761
[TBL] [Abstract][Full Text] [Related]
6. Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular Dystrophy.
Verma S; Nwosu SN; Razdan R; Upadhyayula SR; Phan HC; Koroma AA; Leguizamo I; Correa NS; Kuipa M; Lee D; Vanderford TH; Gardner MR
Hum Gene Ther; 2023 May; 34(9-10):430-438. PubMed ID: 36324212
[TBL] [Abstract][Full Text] [Related]
7. Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A.
Klamroth R; Hayes G; Andreeva T; Gregg K; Suzuki T; Mitha IH; Hardesty B; Shima M; Pollock T; Slev P; Oldenburg J; Ozelo MC; Stieltjes N; Castet SM; Mahlangu J; Peyvandi F; Kazmi R; Schved JF; Leavitt AD; Callaghan M; Pan-Petesch B; Quon DV; Andrews J; Trinh A; Li M; Wong WY
Hum Gene Ther; 2022 Apr; 33(7-8):432-441. PubMed ID: 35156839
[TBL] [Abstract][Full Text] [Related]
8. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes.
Fraldi A; Hemsley K; Crawley A; Lombardi A; Lau A; Sutherland L; Auricchio A; Ballabio A; Hopwood JJ
Hum Mol Genet; 2007 Nov; 16(22):2693-702. PubMed ID: 17725987
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Neutralizing Antibodies against Adeno-Associated Virus Serotypes 1, 2, and 9 in Non-Injected Latin American Patients with Heart Failure-ANVIAS Study.
Sierra-Delgado JA; Likhite S; Bautista PK; Gómez-Ochoa SA; Echeverría LE; Guío E; Vargas C; Serrano NC; Meyer KC; Rincon MY
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982654
[TBL] [Abstract][Full Text] [Related]
10. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.
Rutledge EA; Halbert CL; Russell DW
J Virol; 1998 Jan; 72(1):309-19. PubMed ID: 9420229
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
Boutin S; Monteilhet V; Veron P; Leborgne C; Benveniste O; Montus MF; Masurier C
Hum Gene Ther; 2010 Jun; 21(6):704-12. PubMed ID: 20095819
[TBL] [Abstract][Full Text] [Related]
12. The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: implications for gene therapy and vaccines using AAV1 vector.
Liu Q; Huang W; Zhao C; Zhang L; Meng S; Gao D; Wang Y
J Med Virol; 2013 Sep; 85(9):1550-6. PubMed ID: 23852678
[TBL] [Abstract][Full Text] [Related]
13. Synoviocyte infection with adeno-associated virus (AAV) is neutralized by human synovial fluid from arthritis patients and depends on AAV serotype.
Boissier MC; Lemeiter D; Clavel C; Valvason C; Laroche L; Begue T; Bessis N
Hum Gene Ther; 2007 Jun; 18(6):525-35. PubMed ID: 17532727
[TBL] [Abstract][Full Text] [Related]
14. Adeno-associated virus serotype 1 (AAV1)- and AAV5-antibody complex structures reveal evolutionary commonalities in parvovirus antigenic reactivity.
Tseng YS; Gurda BL; Chipman P; McKenna R; Afione S; Chiorini JA; Muzyczka N; Olson NH; Baker TS; Kleinschmidt J; Agbandje-McKenna M
J Virol; 2015 Feb; 89(3):1794-808. PubMed ID: 25410874
[TBL] [Abstract][Full Text] [Related]
15. The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals.
Mimuro J; Mizukami H; Shima M; Matsushita T; Taki M; Muto S; Higasa S; Sakai M; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
J Med Virol; 2014 Nov; 86(11):1990-7. PubMed ID: 24136735
[TBL] [Abstract][Full Text] [Related]
16. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery.
Fu H; Samulski RJ; McCown TJ; Picornell YJ; Fletcher D; Muenzer J
Mol Ther; 2002 Jan; 5(1):42-9. PubMed ID: 11786044
[TBL] [Abstract][Full Text] [Related]
17. Mucopolysaccharidosis IIIB confers enhanced neonatal intracranial transduction by AAV8 but not by 5, 9 or rh10.
Gilkes JA; Bloom MD; Heldermon CD
Gene Ther; 2016 Mar; 23(3):263-71. PubMed ID: 26674264
[TBL] [Abstract][Full Text] [Related]
18.
Marcó S; Haurigot V; Bosch F
Hum Gene Ther; 2019 Oct; 30(10):1211-1221. PubMed ID: 31482754
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.
Halbert CL; Miller AD; McNamara S; Emerson J; Gibson RL; Ramsey B; Aitken ML
Hum Gene Ther; 2006 Apr; 17(4):440-7. PubMed ID: 16610931
[TBL] [Abstract][Full Text] [Related]
20. Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice.
Passini MA; Watson DJ; Vite CH; Landsburg DJ; Feigenbaum AL; Wolfe JH
J Virol; 2003 Jun; 77(12):7034-40. PubMed ID: 12768022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
